Metformin Improves the Prognosis of Adult Mice with Sepsis-Associated Encephalopathy Better than That of Aged Mice

Gaofei Song,1,2 Huoyan Liang,1,2 Heng Song,1,2 Xianfei Ding,1,2 Dong Wang,1,2 Xiaojuan Zhang,1,2 and Tongwen Sun1,2

1General ICU, The First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Henan Engineering Research Center for Critical Care Medicine, Zhengzhou, China
2Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China

Correspondence should be addressed to Tongwen Sun; suntongwen@163.com

Received 23 December 2021; Revised 8 March 2022; Accepted 6 April 2022; Published 4 May 2022

Academic Editor: Meysam Sarshar

Copyright © 2022 Gaofei Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sepsis-associated encephalopathy (SAE) is often associated with increased ICU occupancy and hospital mortality and poor long-term outcomes, with currently no specific treatment. Pathophysiological mechanisms of SAE are complex and may involve activation of microglia, multiple intracranial inflammatory factors, and inflammatory pathways. We hypothesized that metformin may have an effect on microglia, which affects the prognosis of SAE. In this study, metformin treatment of mice with SAE induced by lipopolysaccharide (LPS) reduced the expression of microglia protein and related inflammatory factors. Poor prognosis of SAE is related to increased expression of tumor necrosis factor-α (TNF-α) and interleukin-1 beta (IL-1β) in brain tissues. Levels of inflammatory cytokines produced by LPS-induced SAE mouse microglia were significantly increased compared with those in the sham group. In addition, ionized calcium-binding adapter molecule 1 (Iba-1) was significantly reduced in metformin-treated SAE mice compared with untreated SAE mice, suggesting that metformin can reduce microgliosis and inhibit central nervous system inflammation, thereby improving patient outcomes. In conclusion, our results stipulate that metformin inhibits inflammation through the adenosine 5′-monophosphate (AMP)-activated protein kinase pathway by inhibiting nuclear factor kappa beta (NF-κB). Metformin can partially reverse the severe prognosis caused by sepsis by blocking microglial proliferation and inhibiting the production of inflammatory factors.

1. Introduction

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [1, 2] and most commonly results in multiple organ dysfunction syndromes in severely affected patients [3]. In sepsis, the central nervous system (CNS) is considered to be one of the first systems involved [4], and the mortality rate increases with the severity of SAE, rising up to 70% [5]. The main clinical outcome is poor prognosis and high mortality rates. SAE is characterized by diffuse brain dysfunction and cognitive impairment as a result of systemic inflammation caused by infection, with clinical manifestations ranging from delirium to coma. However, no clinical or laboratory evidence exist of direct brain infection, brain anatomical abnormalities, cerebral hemorrhage, or cerebral infarction [6]. The pathophysiology of SAE is complex and multifaceted, combining interwoven processes, which lead to numerous functional alterations and disorders, such as neuroinflammation, oxidative stress, reduced brain metabolism, and impaired integrity of the blood-brain barrier (BBB) [7]. In addition, peripheral cytokine storm 8 leads to the production of intracranial inflammatory mediators and plays a key role in the pathogenesis of SAE, mainly manifested as activation of microglia, leukocyte infiltration, and neuronal degeneration. Meanwhile, the permeability of the BBB increases [9], and the infiltration of peripheral inflammatory mediators into the CNS further enhances BBB permeability and promotes the production of inflammatory mediators.

Microglia are important participants in developing the CNS-related disorders, inflammation, and almost all neuropathological conditions, such as stroke, tumors, degenerative
diseases, brain injury, and infection, accounting for approxi-
ately 5–12% of the total number of intracranial cells [10,
11]. These cells have the morphological and functional abil-
ity to adapt to the ever-changing microenvironment around
them. Microglial activation in response to stimulation is
widely believed to promote neurotoxin clearance and main-
tain intracranial homeostasis [12, 13]. Iba-1 is considered to
be a marker protein of microglia [14]. During normal devel-
opment, microglia participate in the clearance of aging neu-
rons through phagocytosis without causing an inflammatory
response [15, 16]. Under pathological conditions such as
SAE, microglia are rapidly activated to produce large
amounts of nitric oxide, TNF-α, IL-6, IL-1, oxygen-free rad-
icals, and various excitatory neurotransmitters. This
expanded inflammatory cascade aggravates neuronal dam-
age, thus damaging the state of consciousness and emotional
states [17, 18]. Activated microglia can produce a variety of
inflammatory factors, such as TNF-α, IL-1β, and NF-κB
[19, 20]. NF-κB, as an inducible transcription factor, plays
a central role in the regulation of inflammatory genes [21].
Lipopolysaccharide (LPS) can strongly stimulate the activa-
tion of microglia and is widely used in the study of neuroin-
flammation [22]. Since disordered activation of microglia
during SAE may lead to exacerbation of existing brain dam-
age, regulation of microglia appears to be a therapeutic
option for SAE [23, 24]. Metformin has been found to
reduce mortality in patients with sepsis significantly. It also
protects the lung tissue from oxidative damage caused by
sepsis [25]. In contrast to other classes of hypoglycemic
drugs, metformin inhibits NF-κB activation through the
adenosine 5’-monophosphate-activated protein kinase
(AMPK) pathway [26]. It more recently has also been shown
to benefit nondiabetic patients by reducing the production
of inflammatory agents and biomarkers of aging [27]. A close
link between reduced AMPK activity and inflammation has
been revealed in the studies of macrophages by Yang et al.
[28]. Moreover, in 2013, Jiang et al. have found that metfor-
mint can reduce intracranial infarction area, cell apoptosis,
and neurological deficits caused by focal cerebral ischemia
through the AMPK autophagy pathway in cerebral ischemia
diseases [29]. However, few studies have focused on the role
of metformin in SAE. Therefore, we aimed to investigate the
effect and potential role of metformin on LPS-induced
inflammation during SAE.

2. Materials and Methods

This study conducted in accordance with the principles out-
lined in the National Institutes of Health (NIH) Guide for
Figure 1: Continued.
including appearance, respiratory rate and quality, presence of eye secretions, activity, and response to stimuli [30]. The higher the score, the more severe the sepsis. When the mouse score reached 21 points, the mice were judged dead. The mice were euthanized immediately, and the brain tissue was removed and stored in liquid nitrogen. Two trained students rated the MSS of the mice.

2.4. Neurobehavioral Score. After MSS score was given to confirm sepsis in mice, a neural score was then used to determine whether the mice had SAE. We scored each group of mice from 8 a.m. to 10 a.m. every day, including auricle reflex, corneal reflex, and escape response. Mice with no reflexes scored 0. One point was scored for the mice whose reflexes were weaker than usual. Mice with normal reflexes scored 2 points [31]. Two trained students rated the MSS of the mice.

2.5. Hematoxylin and Eosin (HE) and Immunofluorescence. We assessed mouse brain tissue previously stored in 4% paraformaldehyde using hematoxylin-eosin (HE) staining. After paraffin embedding, the brain was cut into 4 μm sections and stained with HE. The histological changes of brain tissue were observed under a microscope. Immunofluorescence: after dewaxing and hydration, cells are given permeability, sealed endogenous peroxidase, antigen repair, exposure to antigenic determiners, sealed nonspecific proteins, incubation of primary and secondary antibodies, color rendering after SP reaction, etc. The expression of IBA-1 in the hippocampal CA1, CA3, and DG regions was detected to observe the number of microglia. Microglia were labeled with Cy3 red fluorescence.

2.6. Western Blot Analysis. Previously stored mouse brain tissue was removed from liquid nitrogen. After labeling, brain tissue lysates were prepared, and the protein concentration was determined by the BCA method with reference to the standard curve. The gel was prepared according to the method of polyacrylamide gel, and then the protein was transferred to nitrocellulose membrane by electrophoresis and electric transfer. The protein was sealed with skim milk powder in saline containing Tween (TBST) buffer for 2 hours. The primary antibody solution was prepared according to different antibody instructions. The nitrocellulose membrane was soaked in TBST and incubated in a 4° shaker for 12-16 hours. The nitrocellulose membrane was again incubated with the secondary antibody at room temperature for 2 hours and exposed. Specific bands were detected by chemiluminescence, and the ECL signal was digitally processed by Bandscan 5.0 software.

![Graph](image)

**Figure 1:** (a) Mouse model diagram. (b) MSS score and neurobehavioral score of dentate gyrus of adult mouse brain tissue. (c) MSS score and neurobehavioral score of dentate gyrus of aged mice brain tissue. (d) Survival curves of adult and aged mice. The mice were intraperitoneally injected with LPS, then, given metformin 1 hour later. The vital signs of the mice were observed for the following 7 days, and MSS score and neurobehavioral score were given every day. When the MSS score reached 21, the death was determined, and the brain tissue was dissected for use. In the legend of the survival curve, the mortality rate of the aged mice after LPS administration was significantly higher than that of the adult group, while the effect of metformin treatment in the aged group was significantly lower than that in the adult group. LPS: lipopolysaccharide.

| Groups          | Mortality (number of death/total) | p values |
|-----------------|----------------------------------|----------|
| LPS (adult)     | 70% (7/10)                       | 0.0062 a |
| LPS (aged)      | 90% (9/10)                       |          |
| LPS + M (adult) | 50% (5/10)                       | 0.3613 b |
| LPS + M (aged)  | 70% (7/10)                       |          |

Note. LPS: lipopolysaccharide; LPS + M: lipopolysaccharide + metformin. aComparison with LPS (aged). bComparison with LPS + M (aged). The mortality at 7 days in the LPS (aged) group was significantly higher than that in the LPS (adult) (p < 0.001). The mortality at 7 days in the LPS + M (aged) group was not significantly higher than that in the LPS + M (adult) (p = 0.3613).
2.7. qPCR Analysis. Previously stored brain tissue is removed from liquid nitrogen. Trizol reagent was added after grinding, and the purified total RNA was obtained by two-phase separation, RNA precipitation, RNA cleaning, and precipitation of dissolved RNA after RNA drying in strict accordance with Trizol RNA extraction kit process. The concentration and purity of RNA were measured by spectrophotometer after absorption value. CDNA was prepared according to the instructions of the Uelris RT Mix with DNsae (all-in-one) reverse transcription kit. Hieff®qPCR SYBR Green Master Mix (Low Rox Plus) kit instructions are for amplification. PCR results were analyzed using the $-\Delta \Delta C_{t}$ method. Gene expression data are shown relative to the control, which was set at 100%. Gene expression levels were normalized to those of GAPDH. The primers used are shown in Table 1.

2.8. Statistical Analysis. We used the mean ± SEM to express the data and used the one way analysis of variance and Tukey’s post hoc methods to estimate the differences among the three groups, and $p < 0.05$ was considered significant. The SPSS 21.0 software was used to analyse all results from this study.

3. Result

3.1. Metformin Improves the Prognosis of SAE Mice. When the MSS score of experimental mice reached 21 points, the mice were actively euthanized, and their tissues were dissected and stored in liquid nitrogen. As shown in Figure 1 (b), the MSS scores of the adult LPS group on days 2 and 3 were significantly higher than those of the sham group ($p < 0.05$). Compared with the LPS group, the LPS + M group showed decreased MSS scores at 2–3 days after sepsis induction. As shown in Figure 1(b), the MSS score in the LPS group was significantly higher than that in the sham group ($p < 0.05$), while the LPS + M group had decreased MSS scores, indicating

![Figure 2: (a) Fluorescent staining of adult mouse microglia. (b) Fluorescent staining of aged mice microglia. As shown in figure (a) and (b), microglia were marked with Cy3 red. Activation of microglia in the metformin-treated group was significantly reduced compared with that in the LPS group. As shown by the arrow: activated microglia. In figure (a) and (b), they are shown from top to bottom: the above is the synthesis of the middle and lower figures, and the middle figure: the nuclei are dyed blue by DAPI method; below: microglia IBA-1, shown in red. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. $n = 10$ in each group.](image-url)
that metformin can improve the prognosis of SAE mice. Neurobehavioral scores were used to further observe effects of LPS-induced sepsis in the brain. Scores of the adult and aged LPS groups on days 2 and 3 were significantly lower than those of the sham group. On days 4 and 5 after sepsis induction, the neurobehavioral scores of LPS + M group were increased compared with the LPS group (Figures 1(b) and 1(c)), indicating that metformin improved the neurobehavioral performance of mice with LPS-induced sepsis. The 7-day survival rate of the LPS sepsis-induced mouse model is

Figure 3: (a, b) Effect of metformin on the level of inflammatory factor protein in brain tissue of SAE-induced mice. In figures (a) and (b), the expression level of Iba-1 in LPS + M group was lower than that in LPS group, indicating that metformin could inhibit the activation of microglia. *p < 0.05, **p < 0.01, ***p < 0.001. n = 10 in each group; Iba-1: ionized calcium-binding adapter molecule 1; LPS: lipopolysaccharide; LPS + M: lipopolysaccharide and metformin.
shown in Figure 1(d). In the adult group, the 7-day mortality rates of the sham, LPS, and LPS + M groups were 0%, 70%, and 50%, respectively. The 7-day mortality rates in the old group were 0%, 90%, and 70%, respectively. The mortality rate in the LPS group was significantly higher than that in the sham group ($p < 0.001$) and LPS + M ($p = 0.3613$). In addition, compared with the adult LPS group, increased mortality ($p < 0.001$) was found in the aged LPS group, while there were no statistically significant difference between the aged and the adult LPS + M groups (Table 2).

3.2. Metformin Reduces the Infiltration of Microglia during SAE. In the LPS-induced sepsis model treated with metformin, the immunofluorescence staining of microglia showed that the numbers of microglia in the adult and aged groups were significantly higher than those in the sham groups.
Microglia were significantly reduced in the LPS + M group compared with the LPS group (Figures 2 and 3) \((p < 0.05)\). Western blots showed that the microglial marker Iba-1 was significantly increased in the LPS group \((p \text{ all} < 0.05)\), indicating that microglia were significantly activated in LPS-induced sepsis mice. However, in the LPS + M group, microglial Iba-1 protein expression was decreased compared with that in the LPS group \((p \text{ all} < 0.05)\). These results suggest that metformin can inhibit microglial activation in mice with LPS-induced sepsis (Figures 2 and 3).

### 3.3. Metformin Improves Inflammatory Factor Infiltration into Brain Tissue of SAE Mice

In the LPS-induced SAE model of metformin, inflammatory cell infiltration, disorder of cell arrangement, and cell edema were observed in HE staining of brain tissue in the adult and aged LPS groups, while inflammatory cell infiltration and cell edema were decreased in the adult and aged LPS + M groups compared with their respective LPS groups (Figures 4(a) and 4(b)). Western blot and qPCR showed that TNF-α and IL-1β levels in the LPS group were significantly higher than those in the sham group, while these cytokines were higher than those in the LPS + M group \((p \text{ all} < 0.05)\). Thus, metformin significantly reduced inflammatory cytokines after SAE (Figures 5, 6(a), and 6(b)) \((p \text{ all} < 0.05)\).

### 3.4. The Adult SAE Group Was More Responsive to Metformin than the Aged Group

After metformin treatment, expression levels of inflammatory factors in the adult SAE group were significantly lower than those in the aged group (Figure 6(c)) \((p \text{ all} < 0.05)\). After metformin treatment, p-AMPK and NF-κB levels in the adult SAE group were significantly lower than those in the aged group (Figure 7(c)) \((p \text{ all} < 0.05)\). In conclusion, metformin reduced the inflammatory response in adult mice better than in aged mice.

### 3.5. Metformin Acts on LPS-Induced SAE through AMPK-NF-κB Pathway

Metformin prevents inflammation by inhibiting the transcription factor NF-κB through a pathway dependent on AMPK. We found that NF-κB, TNF-α, and IL-1β protein expression levels were decreased in both adult and aged LPS + M groups compared with the LPS group \((p \text{ all} < 0.05)\), suggesting that metformin alleviates LPS-induced...
inflammatory response through the AMPK-NF-κB pathway, thereby improving the prognosis of SAE (Figures 6(a), 6(b), 7(a), and 7(b)).

4. Discussion

The results of this study established that metformin reduced microglia and various inflammatory factors in mice with LPS-induced SAE and inhibited this inflammatory response by inhibiting nuclear factor NF-κB in an AMPK-dependent pathway, thereby improving prognosis. To the best of our knowledge, we used aged mice as the LPS-induced SAE target for the first time, which was consistent with the prevalence of SAE in aged patients in clinical practice, and can better reflect the pathophysiological status of aged patients.

SAE has an unsatisfactory therapeutic outcome over the course of the disease, and many patients have a poor prognosis and reduced quality of life after treatment. SAE is characterized by an immune response to bacterial endotoxin in the absence of an obvious central infection [32]. People will...
inevitably be infected with viruses, bacteria, and fungi in their whole life. Due to the body’s own immunity, not every time will lead to sepsis. When the body appears aging, major trauma, and other conditions, the overstrong immune response leads to the body’s own organs becoming the target of inflammatory factors, affecting the central nervous system, we call it sepsis-associated encephalopathy [33]. SAE patients often have no obvious infection of the central nervous system, but neuroinflammation and oxidative stress responses are present in brain tissue. Patients can have obvious cognitive dysfunction, memory decline, fuzzy consciousness and coma, and other neurological symptoms [34]. Early in SAE, microglia in the nervous system are rapidly activated and secrete large amounts of cytokines, leading to inflammation of the blood-brain barrier and central nervous system [35]. The function of normal microglia in the central nervous system is to phagocytose and remove damaged nerve cells and tissue fragments, but the continuous inflammatory reaction abnormally enhances the function of microglia, leading to the active attack of normal neurons and nerve tissue in the central nervous system [36]. Therefore, we chose the LPS-induced experimental SAE model and carried out relevant experiments using this model. The LPS-induced SAE model induces the release of multiple inflammatory factors (TNF-α and IL-1β) from microglia, leading to neuronal damage and a severe prognosis [37]. Microglia are “specialized” immune cells of myeloid origin with the function of detecting and removing pathogens, damaged cells, and cell
debris. Activated microglia-mediated neuroinflammation is associated with neuronal death and exacerbation of neurodegenerative disease [38]. Previous studies have demonstrated a correlation between microglia activation and SAE [39]. Overactivation of microglia may account for the poor prognosis of SAE disease [40]. Abnormally activated microglia mediate neuroinflammatory response by producing a variety of proinflammatory factors, which is an important pathological process in CNS diseases [41]. Reducing the activation of microglia, thereby reducing the production of inflammatory factors and subsequent neuronal damage, offers potential treatment options for neuroinflammatory diseases [42, 43]. IL-1β has been implicated in a variety of CNS diseases, most of which are associated with inflammatory processes [44]. Microglia play an increasingly important role in the treatment of SAE and may be a new therapeutic target [45, 46]. In our study, immunofluorescence showed that a large number of microglia were activated in the LPS target [45, 46]. In our study, immuno-therapy processes [44]. Microglia play an increasingly important role in the treatment of SAE and may be a new therapeutic target [45, 46]. In our study, immunofluorescence showed that a large number of microglia were activated in the LPS group, while fewer microglia were activated in the LPS+M group (Figures 4(a) and 4(b)). These results showed that metformin reduced the number of microglia in mice with LPS-induced SAE and improved their prognosis.

To further investigate the possible effects of metformin on microglia during LPS-induced SAE, we examined expression levels of inflammatory cytokines at the protein and gene levels. Inhibition of NF-κB signal transduction can reduce LPS-induced microglial inflammatory mediators, thereby reducing intracranial inflammation and improving prognosis [47, 48]. According to western blotting and qPCR results, metformin can inhibit LPS-induced TNF-α, IL-1β, and NF-κB production. Excessive microglial production, which in turn produces excess pro-inflammatory factors, leads to neuronal damage [49, 50]. Amoani et al. found that high dose of metformin in peripheral blood circulation can inhibit TNF-α production and indirectly reduce inflammatory response [51]. Some studies have found that metformin can promote the conversion of microglia from the M1 (proinflammatory type to the M2 (anti-inflammatory) type, which has been shown to protect nerve cells [52]. In the aged animals, Senescence-associated secretory proteins (SASP) can release inflammatory factors and subsequently neuronal damage, thereby reducing the production of related inflammatory factors [52, 53]. Metformin indirectly alleviates inflammation by inhibiting NF-κB production and reducing SASP secretion [55, 56]. The potential mechanisms whereby metformin reduces cardiovascular disease incidence and all-cause mortality have been actively investigated. Metformin not only alleviates hyperglycemia and insulin resistance [57, 58] but also other cardiovascular risk factors, such as overweight or obesity, atherosclerosis, blood pressure, procoagulant state and thrombosis, and carotid intima thickening [59, 60]. In addition, metformin treatment reduced the numbers of pathogenic Th17 cells and increased the numbers of regulatory T cells, thereby limiting the inflammatory response [61, 62]. Some studies have shown that patients with sepsis treated with chronic metformin have a lower mortality rate than patients not treated with metformin [63]. Other studies have shown no differences in serum lactate clearance between patients with sepsis treated with chronic metformin and those not treated with metformin [64]. Although antibacterial effects of metformin are not fully understood, the underlying metabolic mechanisms of metformin are widely attributed to the activation of AMPK [65]. Toejing et al. found that metformin ameliorates endotoxemia and inflammation through the AMPK-NF-κB pathway [31, 66]. Mammalian AMPK is generally thought of as a sensor for adenine nucleotides, activated in a state of low cellular energy. It restores energy balance by turning on catabolic pathways that produce ATP, while shutting down anabolic pathways and other ATP-consuming processes [67, 68]. During SAE, impaired intracranial hemodynamics result in reduced oxygen and energy supply to microglia and neurons, ultimately leading to AMPK activation. Jian et al. found that AMPK is also involved in inflammatory responses by regulating NF-κB signaling [69]. Wang et al. reported that activation of AMPK downregulates NF-κB pathway function [70, 71], with phosphorylated AMPK inhibiting NF-κB activation and decreasing IL-1β and TNF-α production [72, 73]. These results suggest that AMPK/NF-κB may play an important role in reducing the inflammatory response and improving prognosis during SAE [74]. In the peripheral system, metformin alleviates LPS-induced macrophage-induced acute lung injury through the AMPK pathway [75]. Microglia are considered to function as macrophages in the central nervous system, and our study demonstrates that metformin reduces SAE-induced inflammation by reducing microglia activation. In our experiment, the MSS and neurobehavioral scores were used to determine the occurrence and severity of sepsis. Western blotting and qPCR showed that the expression of IL-1β and TNF-α decreased in the LPS + M group. Metformin may improve the prognosis of mice by inhibiting the release of related inflammatory factors through the AMPK-NF-κB pathway. Our results also showed that metformin treatment in the adult LPS group was more effective than in the aged LPS group.

The shortcomings of this paper is that we did not conduct further cell experiments to verify the inflammatory pathways. And we tried to mimic the human condition of geriatric sepsis in aged mice, but we gave metformin only once. If we inject metformin intraperitoneally for 14 consecutive days in aged mice, and then inject LPS intraperitoneally to create sepsis model, it may be more consistent with the human disease model and may better reflect the role of metformin in the treatment of sepsis.

5. Conclusion

Overall, our results suggest that metformin reduces microglia and various inflammatory factors in mice with LPS-induced SAE and may inhibit the inflammatory response by inhibiting NF-κB in an AMPK-dependent pathway, thereby improving prognosis. The expression of inflammatory factors in adult mice was lower than that in aged mice, suggesting that metformin treatment in adult mice was more effective compared with older mice. It can be concluded that the protective potential of metformin is worth considering to
reduce the inflammatory responses during SAE to improve prognosis.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Conceptualization was done by GFS and HYL; methodology was done by GFS, HYL, XFD, and DW; validation was done by GFS and XJZ; formal analysis was done by GFS; investigation was done by GFS; resources were done by GFS and HS; data curation was done by GFS and HS; writing—original draft preparation was done by GFS; writing—review and editing was done by GFS, HYL, and TWS; project administration was done by GFS and TWS; funding acquisition was done by TWS. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

This study was supported by the United Fund of National Natural Science Foundation of China (Grant no. U2004110) and Leading Talents Fund in Science and Technology Innovation in Henan Province (Grant no. 194200510017).

References

[1] P. E. Marik, “Critical illness-related corticosteroid insufficiency,” Chest, vol. 135, no. 1, pp. 181–193, 2009.
[2] C. W. Seymour, V. X. Liu, T. J. Iwashyna et al., “Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3),” Journal of the American Medical Association, vol. 315, no. 8, pp. 762–774, 2016.
[3] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (sepsis-3),” Journal of the American Medical Association, vol. 315, no. 8, pp. 801–810, 2016.
[4] D. L. Helbling, L. Böhm, and O. W. Witte, “Sepsis-associated encephalopathy,” Canadian Medical Association Journal, vol. 190, no. 36, p. E1083, 2018.
[5] T. E. Golton and G. B. Young, “Sepsis-associated encephalopathy,” Nature reviews. Neurology, vol. 8, no. 10, pp. 557–566, 2012.
[6] A. Semmler, S. Herrmann, F. Mormann et al., “Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism,” Journal of Neuroinflammation, vol. 5, no. 1, p. 38, 2008.
[7] A. V. Catarina, G. Branchini, L. Bettoni, J. R. De Oliveira, and F. B. Nunes, “Sepsis-associated encephalopathy: from pathophysiology to progress in experimental studies,” Molecular Neurobiology, vol. 58, no. 6, pp. 2770–2779, 2021.
[8] D. C. Fajgenbaum and C. H. June, “Cytokine storm,” New England Journal of Medicine, vol. 383, no. 23, pp. 2255–2273, 2020.
[9] M. D. Sweeney, Z. Zhao, A. Montagne, A. R. Nelson, and B. V. Zlokovic, “Blood-brain barrier: from physiology to disease and back,” Physiological Reviews, vol. 99, no. 1, pp. 21–78, 2019.
[10] J. El Khoury, “Neurodegeneration and the neuroimmune system,” Nature Medicine, vol. 16, no. 12, pp. 1369–1370, 2010.
[11] R. M. Ransohoff and J. El Khoury, “Microglia in health and disease,” Cold Spring Harbor Perspectives in Biology, vol. 8, no. 1, article a020560, 2015.
[12] U. K. Hanisch and H. Kettenmann, “Microglia: active sensor and versatile effector cells in the normal and pathologic brain,” Nature Neuroscience, vol. 10, no. 11, pp. 1387–1394, 2007.
[13] C. N. Parkhurst, G. Yang, I. Ninan et al., “Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor,” Cell, vol. 155, no. 7, pp. 1596–1609, 2013.
[14] D. M. Norden, P. J. Trojanowski, E. Villanueva, E. Navarro, and J. P. Godbout, “Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge,” Glia, vol. 64, no. 2, pp. 300–316, 2016.
[15] J. L. Marín-Teva, I. Dusart, C. Colin, A. Gervais, N. van Rooijen, and M. Mallat, “Microglia promote the death of developing Purkinje cells,” Neuron, vol. 41, no. 4, pp. 535–547, 2004.
[16] M. Hirotsuka, D. Cuthill, V. Zbarsky et al., “Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development,” Glia, vol. 58, no. 1, pp. 11–28, 2010.
[17] A. Cagnin, D. J. Brooks, A. M. Kennedy et al., “In-vivo measurement of activated microglia in dementia,” Lancet (London, England), vol. 358, no. 9280, pp. 461–467, 2001.
[18] H. Kerem-Shaul, A. Spinrad, A. Weiner et al., “A unique microglia type associated with restricting development of Alzheimer’s disease,” Cell, vol. 169, no. 7, pp. 1276–1290.e17, 2017.
[19] M. Yamamoto, T. Kiyota, M. Horiba et al., “Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice,” The American Journal of Pathology, vol. 170, no. 2, pp. 680–692, 2007.
[20] Y. F. Liao, B. J. Wang, H. T. Cheng, L. H. Kuo, and M. S. Wolfe, “Tumor necrosis factor-α, interleukin-1β, and interferon-γ stimulate γ-secretase-mediated cleavage of amyloid precursor protein through a JNK- dependent MAPK pathway,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 49523–49532, 2004.
[21] Y. Ma, J. Liu, H. Shi, and L. L. Yu, “Isolation and characterization of anti-inflammatory peptides derived from whey protein,” Journal of Dairy Science, vol. 99, no. 9, pp. 6902–6912, 2016.
[22] J. S. Lee, Y. J. Jeon, J. Y. Kang, S. K. Lee, H. D. Lee, and C. G. Son, “Aquilariae lignum methylene chloride fraction attenuates IL-1β-driven neuroinflammation in BV2 microglial cells,” International Journal of Molecular Sciences, vol. 21, no. 15, p. 5465, 2020.
[23] C. Murray, D. J. Sanderson, C. Barkus et al., “Systemic inflammation induces acute working memory deficits in the primed brain: relevance for delirium,” Neurobiology of Aging, vol. 33, no. 3, pp. 603–616.e3, 2012.
[24] C. A. Moraes, G. Santos, J. C. D’Avila et al., “Activated microglia-induced deficits in excitatory synapses through IL-1β: implications for cognitive impairment in sepsis,” Molecular Neurobiology, vol. 52, no. 1, pp. 653–663, 2015.
H. Ghavimi, S. Sheidaei, H. Vaez, E. Zolali, P. Asgharian, and H. Hamishehkar, “Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin,” *Iranian Journal of Basic Medical Sciences*, vol. 21, no. 5, pp. 469–475, 2018.

Y. Saihno, “Metformin and inflammation: its potential beyond glucose-lowering effect,” *Endocrine, Metabolic & Immune Disorders Drug Targets*, vol. 15, no. 3, pp. 196–205, 2015.

M. Pollak, “The effects of metformin on gut microbiota and the immune system as research frontiers,” *Diabetologia*, vol. 60, no. 9, pp. 1662–1667, 2017.

Z. Yang, B. B. Kahn, H. Shi, and B. Z. Xue, “Macrophage a1 AMP-activated protein kinase (a1AMPK) antagonizes fatty acid-induced inflammation through SIRT1,” *The Journal of Biological Chemistry*, vol. 285, no. 25, pp. 19051–19059, 2010.

T. Jiang, J. T. Yu, X. C. Zhu et al., “Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy,” *British Journal of Pharmacology*, vol. 171, no. 13, pp. 3146–3157, 2014.

B. Shrum, R. V. Anantha, S. X. Xu et al., “A robust scoring system to evaluate sepsis severity in an animal model,” *BMC Research Notes*, vol. 7, no. 1, p. 233, 2014.

I. M. Kafa, M. Uysal, S. Bakirci, and K. M. Ayberk, “Sepsis induces apoptotic cell death in different regions of the brain in a rat model of sepsis,” *Acta Neurobiologiae Experimentalis*, vol. 70, no. 3, pp. 246–260, 2010.

M. Schellowski, H. Engler, and J. S. Grigolet, “Endotoxin-induced experimental systemic inflammation in humans: a model to disentangle immune-to-brain communication,” *Brain, Behavior, and Immunity*, vol. 35, pp. 1–8, 2014.

J. Rello, F. Valenzuela-Sánchez, M. Ruiz-Rodriguez, and S. Moyano, “Sepsis: a review of advances in management,” *Advances in Therapy*, vol. 34, no. 11, pp. 2393–2411, 2017.

A. A. Jesus, P. Passaglia, B. M. Santos et al., “Chronic molecular hydrogen inhalation mitigates short and long-term memory loss in polymicrobial sepsis,” *Brain Research*, vol. 1739, p. 146857, 2020.

X. Peng, Z. Luo, S. He, L. Zhang, and Y. Li, “Blood-brain barrier disruption by lipopolysaccharide and sepsis-associated encephalopathy,” *Frontiers in Cellular and Infection Microbiology*, vol. 11, article 768108, 2021.

K. E. Zengeler and J. R. Lukens, “Innate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders,” *Nature reviews. Immunology*, vol. 21, no. 7, pp. 454–468, 2021.

H. Noh, J. Jeon, and H. Seo, “Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain,” *Neurochemistry International*, vol. 69, pp. 35–40, 2014.

M. L. Block and J. S. Hong, “Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism,” *Progress in Neurobiology*, vol. 76, no. 2, pp. 77–98, 2005.

J. J. Hoomezans, E. S. van Haastert, A. J. Rozemuller, P. Eikelenboom, and W. A. van Gool, “Microglia activation in sepsis: a case-control study,” *Journal of Neuroinflammation*, vol. 4, no. 1, p. 4, 2007.

R. Sonnevile, E. de Montmollin, J. Poulade et al., “Potentially modifiable factors contributing to sepsis-associated encephalopathy,” *Intensive Care Medicine*, vol. 43, no. 8, pp. 1075–1084, 2017.

M. S. Subbarayan, C. Hudson, L. D. Moss, K. R. Nash, and P. C. Bickford, “T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson’s disease,” *Journal of Neuroinflammation*, vol. 17, no. 1, p. 242, 2020.

A. M. Mohamed, M. Z. Habib, M. A. Ebeid et al., “Amisulpride alleviates chronic mild stress-induced cognitive deficits: role of prefrontal cortex microglia and Wnt/b-catenin pathway,” *European Journal of Pharmacology*, vol. 885, p. 173411, 2020.

Y. Chen, J. X. Sun, W. K. Chen et al., “miR-124/VAMP3 is a novel therapeutic target for mitigation of surgical trauma-induced microglial activation,” *Signal Transduction and Targeted Therapy*, vol. 4, no. 1, p. 27, 2019.

A. S. Mendiola and A. E. Cardona, “The IL-1β phenomena in neuroinflammatory diseases,” *Journal of Neural Transmission*, vol. 125, no. 5, pp. 781–795, 2018.

S. Beggs and M. W. Salter, “SnapShot: microglia in disease,” *Cell*, vol. 165, no. 5, pp. 1294–1294.e1, 2016.

D. M. Sui, Q. Xie, W. J. Yi et al., “Resveratrol protects against sepsis-associated encephalopathy and inhibits the NLRP3/IL-1β axis in microglia,” *Mediators of Inflammation*, vol. 2016, 1045610 pages, 2016.

S. Yang, S. Chu, Q. Ai et al., “Anti-inflammatory effects of higenamine (Hig) on LPS-activated mouse microglia (BV2) through NF-κB and Nrf2/HO-1 signaling pathways,” *International Immunopharmacology*, vol. 85, p. 106629, 2020.

V. R. Venna, G. Weston, S. E. Benashski et al., “NF-κB contributes to the detrimental effects of social isolation after experimental stroke,” *Acta Neuropathologica*, vol. 124, no. 3, pp. 425–438, 2012.

D. N. Xanthos and J. Sandkühler, “Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity,” *Nature Reviews. Neuroscience*, vol. 15, pp. 43–53, 2014.

Y. W. Wang, Q. Zhou, X. Zhang et al., “Mild endoplasmic reticulum stress ameliorates lipopolysaccharide-induced neuroinflammation and cognitive impairment via regulation of microglial polarization,” *Journal of Neuroinflammation*, vol. 14, no. 1, p. 233, 2017.

B. Amoani, S. A. Sakyi, R. Mantey et al., “Increased metformin dosage suppresses pro-inflammatory cytokine levels in systemic circulation and might contribute to its beneficial effects,” *Journal of Immunoussay & Immunochemistry*, vol. 42, no. 3, pp. 252–264, 2021.

Y. Q. Wu, J. Xiong, Z. L. He et al., “Metformin promotes microglial cells to facilitate myelin debris clearance and accelerate nerve repairment after spinal cord injury,” *Acta Pharmacologica Sinica*, 2021.

A. K. Palmer, T. Tchkonia, N. K. LeBrasseur, E. N. Chini, M. Xu, and J. L. Kirkland, “Cellular senescence in type 2 diabetes: a therapeutic opportunity,” *Diabetes*, vol. 64, no. 7, pp. 2289–2298, 2015.

J. P. Coppé, P. Y. Desprez, A. Krtolica, and J. Campisi, “The senescence-associated secretory phenotype: the dark side of tumor suppression,” *Annual Review of Pathology*, vol. 5, no. 1, pp. 99–118, 2010.

H. C. Xiang, L. X. Lin, X. F. Hu et al., “AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression,” *Journal of Neuroinflammation*, vol. 16, no. 1, p. 34, 2019.
AMPK: guardian of metabolism and mitochondrial homeostasis, Nature Reviews. Molecular Cell Biology, vol. 19, no. 2, pp. 121–135, 2018.

P. Toejing, N. Khat-Udomkiri, J. Intaklad, S. Sirilun, C. Chaiyasut, and N. Lalerd, “Putative mechanisms responsible for the antihyperglycemic action of lactobacillus paracasei HII01 in experimental type 2 diabetic rats,” Nutrients, vol. 12, no. 10, p. 3015, 2020.

S. C. Lin and D. G. Hardie, “AMPK: sensing glucose as well as cellular energy status,” Cell Metabolism, vol. 27, no. 2, pp. 299–313, 2018.

D. Garcia and R. J. Shaw, “AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance,” Molecular Cell, vol. 66, no. 6, pp. 789–800, 2017.

M. Jian, J. Kwan, M. Bunting, R. Ng, and C. KJ Jon, “Adiponectin suppresses amyloid-β oligomer (AβO)-induced inflammatory response of microglia via AdipoR1-AMPK-NF-κB signaling pathway,” Journal of Neuroinflammation, vol. 16, no. 1, pp. 1–19, 2019.

S. Wang, M. Zhang, B. Liang et al., “AMPKα2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes,” Circulation Research, vol. 106, no. 6, pp. 1117–1128, 2010.

Y. Hattori, K. Suzuki, S. Hattori, and K. Kasai, “Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells,” Hypertension, vol. 47, no. 6, pp. 1183–1188, 2006.

I. P. Salt and T. M. Palmer, “Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation,” Expert Opinion on Investigational Drugs, vol. 21, no. 8, pp. 1155–1167, 2012.

A. Thiirupathi and C. T. de Souza, “Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise,” Journal of Physiology and Biochemistry, vol. 73, no. 4, pp. 487–494, 2017.

L. A. O’Neill and D. G. Hardie, “Metabolism of inflammation limited by AMPK and pseudo-starvation,” Nature, vol. 493, no. 7432, pp. 346–355, 2013.

X. Zhang, F. Shang, L. Hui, K. Zang, and G. Sun, “The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism,” Saudi Pharmaceutical Journal, vol. 25, no. 4, pp. 666–670, 2017.